JP6411893B2 - （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型 - Google Patents

（ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型 Download PDF

Info

Publication number
JP6411893B2
JP6411893B2 JP2014545450A JP2014545450A JP6411893B2 JP 6411893 B2 JP6411893 B2 JP 6411893B2 JP 2014545450 A JP2014545450 A JP 2014545450A JP 2014545450 A JP2014545450 A JP 2014545450A JP 6411893 B2 JP6411893 B2 JP 6411893B2
Authority
JP
Japan
Prior art keywords
pain
hydroxybenzene
propyl
phenylpropylamide
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014545450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500831A5 (https=
JP2015500831A (ja
Inventor
カプラン，エリアフ
Original Assignee
ノヴァレメド リミテッド
ノヴァレメド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴァレメド リミテッド, ノヴァレメド リミテッド filed Critical ノヴァレメド リミテッド
Publication of JP2015500831A publication Critical patent/JP2015500831A/ja
Publication of JP2015500831A5 publication Critical patent/JP2015500831A5/ja
Application granted granted Critical
Publication of JP6411893B2 publication Critical patent/JP6411893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014545450A 2011-12-08 2012-12-06 （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型 Active JP6411893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568219P 2011-12-08 2011-12-08
US61/568,219 2011-12-08
PCT/IL2012/050512 WO2013084238A1 (en) 2011-12-08 2012-12-06 Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017142137A Division JP2018021023A (ja) 2011-12-08 2017-07-21 （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型

Publications (3)

Publication Number Publication Date
JP2015500831A JP2015500831A (ja) 2015-01-08
JP2015500831A5 JP2015500831A5 (https=) 2017-09-14
JP6411893B2 true JP6411893B2 (ja) 2018-10-31

Family

ID=48573665

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014545450A Active JP6411893B2 (ja) 2011-12-08 2012-12-06 （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型
JP2017142137A Pending JP2018021023A (ja) 2011-12-08 2017-07-21 （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017142137A Pending JP2018021023A (ja) 2011-12-08 2017-07-21 （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型

Country Status (11)

Country Link
US (1) US9381173B2 (https=)
EP (1) EP2788317B1 (https=)
JP (2) JP6411893B2 (https=)
CN (1) CN103998420B (https=)
AU (1) AU2012348529B2 (https=)
CA (1) CA2856665C (https=)
DK (1) DK2788317T3 (https=)
ES (1) ES2763946T3 (https=)
HU (1) HUE048570T2 (https=)
IN (1) IN2014MN00919A (https=)
WO (1) WO2013084238A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173813A1 (en) * 2014-05-14 2015-11-19 Novaremed Ltd. Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes
KR102062268B1 (ko) 2018-05-18 2020-01-03 한국교통대학교 산학협력단 발광 특성 또는 전하 전달 특성이 우수한 아지드계 가교제
CN113329746B (zh) * 2019-01-23 2025-05-02 诺瓦麦有限公司 用于治疗或预防疼痛、炎症和/或自身免疫的化合物
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
WO2026037478A1 (en) 2023-08-11 2026-02-19 Novaremed AG (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546088B1 (en) 2002-10-03 2014-12-17 Novaremed Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP4939396B2 (ja) 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
US20090197781A1 (en) 2008-01-31 2009-08-06 Hari Babu Sunkara Wellbore Fluids Comprising Poly(trimethylene ether) glycol Polymers
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
EP2475361B1 (en) 2009-09-09 2019-11-06 Novaremed Ltd. N-substituted benzenepropanamides for use in the treatment of pain and inflammation
GB0916073D0 (en) 2009-09-14 2009-10-28 Cintec Int Ltd Improvements in and relating to building anchor systems

Also Published As

Publication number Publication date
AU2012348529B2 (en) 2017-03-30
HK1201059A1 (en) 2015-08-21
EP2788317B1 (en) 2019-10-02
WO2013084238A1 (en) 2013-06-13
DK2788317T3 (da) 2020-01-20
JP2015500831A (ja) 2015-01-08
EP2788317A4 (en) 2015-07-08
US9381173B2 (en) 2016-07-05
IN2014MN00919A (https=) 2015-04-17
CA2856665A1 (en) 2013-06-13
CN103998420A (zh) 2014-08-20
US20140275270A1 (en) 2014-09-18
JP2018021023A (ja) 2018-02-08
ES2763946T3 (es) 2020-06-01
AU2012348529A1 (en) 2014-06-12
CN103998420B (zh) 2018-04-17
HUE048570T2 (hu) 2020-08-28
CA2856665C (en) 2019-11-12
EP2788317A1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
EP0934061B1 (en) Isobutylgaba and its derivatives for the treatment of pain
CA2255652E (en) Isobutylgaba and its derivatives for the treatment of pain
JP2018021023A (ja) （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型
KR100557852B1 (ko) 이통증 또는 다른 여러가지 타입의 만성동통 또는 환상통을 치료하는데 쓰이는 의약 조성물
JP2019048820A (ja) メチルナルトレキソンの経口組成物を用いたオピオイド誘導性便秘症の治療及び予防のための方法
EP2705843A1 (en) Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
HUE035071T2 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
Deshmukh et al. Review on analgesic activity and determination methods
EP3860582B1 (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
HK1201059B (en) Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide
JP2016528289A (ja) ジエチル（２−シアノエチル）ホスホネートの医薬組成物および使用
HK40061961A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
HK40061961B (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
BRPI0613281A2 (pt) combinação terapêutica contendo um bloqueador de receptor nmda e uma substáncia analgésica e narcótica
HK1021134B (en) Isobutylgaba and its derivatives for the treatment of pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170721

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170912

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180927

R150 Certificate of patent or registration of utility model

Ref document number: 6411893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250